Skip to main content

Table 4 Summary of previously published series

From: Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?

Article Histological subtype No of samples Smoking status Concordance PT/M Analysis within PT Concordance within PT Method Mutation type Metastatic sites
Yatabe et al. 2011[17] ADC (77) 77   100    qPCR L858R Lymph nodes
        Fragment analysis DEL19  
         INS20  
         719X  
Sun et al. 2011[37] ADC (39), SCC (31), ADSQ (6), LCC (4) 80 Ever (49)     Direct sequencing all Lymph nodes
    Never (31)       
    Global 92,5% (74/80)      
Wei et al. 2014[41] ADC (49) 50 Ever (10) 80%    qPCR (commercial kit) 45 hotspots Lymph nodes
  SCC (1)         
    Never (40) 97,5%      
    Global 93% (47/50)      
Bai et al. 2013[36] ADC (63) 85 (45 EGFRmt 40 EGFRwt)    1431 foci 87,1% ARMS DXS EGFR mutation Kit  
  SCC (10)     1238 foci (foci : capture with laser microdissection 0,1cm2) 4 cases with 5% - 8% of foci showing mutations    
  ADSQ (5)         
  Other (7)         
Chang et al. 2011[42] ADC (34) 56 (27 EGFRmt) Ever (29) 62%    Direct sequencing all Lymph nodes
  SCC (17)         
  ADSQ (1)   Never (23) 70%      
  Other (1)   Unknown (4)       
    Global 68% (38/56)      
Schmid et al. 2009[33] ADC (96) 96 (7 EGFRmt) Ever (74)     Direct sequencing L858R (3) Lymph nodes
         DEL19 (3)  
    Never (22)      INS20 (1)  
    Global 14% (1/7)      
Gow et al 2009[34] ADC (42) 67 (35 EGFRmt) Ever (26)     Direct sequencing and ARMS for discordant results all Brain (25)
  SCC (21)         Bone (20)
  ADSQ (0) (19 with adjuvant treatment before molecular analysis on metastatic site) Never (41)       Other (22)
  Other (4)   Global 26% (9/35) seq and 57 %(20/35) ARMS      
Mattsson et al. 2012[18] ADC (6) 6    3 foci per tumor (distinct morphologies) 100% Direct sequencing L858R and DEL19  
Kalikaki et al. 2008[35] ADC (20) 25 (7 EGFRmt) Ever (22)     Direct sequencing all Brain (3)
  SCC (2)         Pleura (5)
  ADSQ (0) (17 with adjuvant treatment before molecular analysis on metastatic site) Never (3)       Lung (9)
  Other (3)   Global 14% (1/7) 5 mutations are rare alterations (codons 692-847-746-857)      Adrenal gland (3)
          Bone (2)
          Skin (1)
          Liver (1)
Matsumoto et al. 2006[43] ADC (19) 19 (12 EGFRmut)   100%    Direct sequencing L858R, DEL19 Brain (19)
Yatabe et al. 2011[17] ADC (50) 50 EGFRmt    3 foci per tumor (50) 100% qPCR L858R  
        Fragment analysis DEL19  
      100 foci per tumor (5) 100%    
  1. Schematic review of previously published series comparing primary tumor and metastasis or different loci within primary tumor. Tumor type, smoking status, detection methods, mutation tested and metastatic sites are given. PT : primary Tumor, M: metastasis, ADC: adenocarcinoma, SCC: squamous cell carcinoma, ADSQ : adenosquamous carcinoma, LCC: large cell carcinoma mt: mutated, wt : wild type, ARMS: amplification refractory mutation system.